A multicentre, open label, non-randomized, phase 1b trial of NG-350A, a tumourselective anti-CD40-expressing adenoviral vector, in combination with chemoradiotherapy in locally advanced rectal cancer (FORTRESS)

The purpose of this research is to test an investigational drug called NG-350A as a possible treatment for locally advanced rectal cancer (LARC). An investigational drug is one that has not been approved by regulatory agencies.